(VIANEWS) – Shares of Inovio Pharmaceuticals (NASDAQ: INO) fell by a staggering 27.27% in 21 sessions from $1.54 at 2023-02-14, to $1.12 at 10:40 EST on Thursday, after two consecutive sessions in a row of losses. NASDAQ is dropping 0.11% to $11,421.11, after three successive sessions in a row of gains.
Inovio Pharmaceuticals’s last close was $1.15, 71.25% below its 52-week high of $4.00.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Earnings Per Share
As for profitability, Inovio Pharmaceuticals has a trailing twelve months EPS of $-1.073.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -92.27%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 66% and 52.8%, respectively.
Sales Growth
Inovio Pharmaceuticals’s sales growth is negative 59.5% for the ongoing quarter and 0.5% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 3038.2%, now sitting on 10.98M for the twelve trailing months.
More news about Inovio Pharmaceuticals (INO).
